In a recent edition of *Critical Care*, on behalf of the Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation study investigators, Shekar and colleagues assessed meropenem pharmacokinetics (PK) in patients receiving extracorporeal membrane oxygenation (ECMO), with or without continuous renal replacement therapy (CRRT) \[[@CR1]\].

Patients on ECMO commonly have infections, reaching rates of more than 15 per 1,000 ECMO days according to data pooled from the Extracorporeal Life Support Organization Registry \[[@CR2]\], and these infections are associated with increased mortality. There is also increasing evidence that initial antibiotic appropriateness impacts the outcome of severe infections. To ensure maximal bacterial killing, antibiotics should achieve adequate exposure as soon as possible; that is, an adequate concentration during an ideal time, according to the antibiotic's characteristics. Consequently, not only starting an antibiotic but also selecting an ideal dose is crucial for therapeutic success.

High antibiotic doses are usually needed to achieve therapeutic concentrations early in the infection course. This has been shown for β-lactams \[[@CR3]\], vancomycin \[[@CR4]\] and aminoglycosides \[[@CR5]\], implying the need for higher than recommended doses. These high doses may also be necessary to overcome the impact of bacteria resistance, especially for hospital-acquired infections.

Antibiotics are usually prescribed in a traditional pattern, taking into account only the existence of renal or liver dysfunction and considering the susceptibility pattern of the microorganism. Moreover, the antibiotic dose is usually maintained throughout the treatment course, although significant PK changes occur from the resuscitation phase to the recovery phase \[[@CR6]\].

Ideally, individualized dosing strategies should account for the altered PK and pathogen susceptibility in each patient. In order to achieve this goal it is necessary to understand the full impact of therapeutic interventions and patient characteristics on antibiotic PK.

Drug dosing in critically ill patients is especially challenging due to the frequent and hard to predict changes in PK, especially the increased volume of distribution and clearance variation \[[@CR7]\], secondary to volume resuscitation, increased cardiac output and capillary leak. Several therapeutic procedures are also associated with PK changes, and both CRRT and ECMO are among the most challenging. In fact the inflammatory activation induced by the extracorporeal circulation and exposure of blood to foreign material and the drug sequestration in the circuit \[[@CR8]\] both contribute to alteration in antibiotic concentration and half-life.

ECMO is among the most rapidly increasing support techniques in intensive care \[[@CR9]\], and its use in the United States has increased more than four times in a space of only 5 years. Understanding the technique's impact on antibiotic PK is therefore essential.

In their study, Shekar and colleagues showed that the volume of distribution of meropenem is increased in patients undergoing ECMO (with or without CRRT) and consequently high initial antibiotic doses were commonly needed \[[@CR1]\]. On the other hand, clearance was usually low, correlated with CRRT and with creatinine clearance, so subsequent doses had to be adjusted. Although conventional dosing was able to achieve a trough concentration \>2 mg/dl in all patients, a higher target (\>8 mg/dl) was only obtained when higher doses were used \[[@CR1]\]. These conclusions were in line with another recently published study that accessed patients undergoing CRRT \[[@CR10]\]: conventional dosing was not able to achieve the intended target concentrations in all patients, but increasing doses also exposed several patients to toxicity.

Therapeutic drug monitoring has been shown to facilitate the achievement of adequate antibiotic concentration \[[@CR11]\]. Unfortunately this treatment is only routinely available for vancomycin and aminoglycosides. Studies addressing β-lactam antibiotics PK, however, have also unveiled underdosing and toxic accumulation \[[@CR12]\] due to large interindividual and intraindividual variability, suggesting the need to tailor the antibiotic dose to the patient and to adjust it according to PK changes \[[@CR13],[@CR14]\].

The study by Shekar and colleagues is part of a larger multicentric effort aimed at the determination of PK of multiple drugs, namely sedatives, opioids, antibiotics and antifungals, in ECMO patients \[[@CR15]\]. This study is a painstaking work of undeniable importance that will culminate in the determination of evidence-based guidelines for drug therapy dosage during ECMO.

In conclusion, we can clearly no longer rely on the 'one size fits all' paradigm when choosing the antibiotic dose. Knowledge of antibiotic PK, patient status and immune function, bacteria virulence, susceptibility and inoculum, as well as the PK impact of different therapies, should all contribute to dose selection.
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